Skip to main content

Why have neuroprotectants failed?

Lessons learned from stroke trials

Journal of Neurology volume 252, pages 1011–1020 (2005)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

£ 29.95

Price includes VAT (United Kingdom)
Tax calculation will be finalised during checkout.

References

  1. Feigin VL, Lawes CMM, Bennett DA, Anderson CS (2003) Stroke epidemiology: a review of population-based studies of the incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2:43–53

    Article  PubMed  Google Scholar 

  2. Martinez-Vila E, Sieira PI (2001) Current status and perspectives of neuroprotection in ischemic stroke treatment. Cerebrovasc Dis 11(Suppl 1):60–70

    Article  PubMed  Google Scholar 

  3. Lees KR (2002) Management of acute stroke. Lancet Neurol 1:41–50

    Article  PubMed  Google Scholar 

  4. Fang J, Alderman MH (2001) Trend of stroke hospitalization, United States, 1988–1997. Stroke 32:2221–2226

    PubMed  Google Scholar 

  5. Howard G, Howard VJ, Katholi C, Oli MK, Huston S (2001) Decline in US stroke mortality: an analysis of temporal patterns by sex, race, and geographic region. Stroke 32:2213–2220

    PubMed  Google Scholar 

  6. Michaud CM, Murray CJ, Bloom BR (2001) Burden of disease–implications for future research. JAMA 285:535–539

    Article  PubMed  Google Scholar 

  7. Fisher M, Schaebitz W (2000) An overview of acute stroke therapy: past, present, and future. Arch Intern Med 160:3196–3206

    Article  PubMed  Google Scholar 

  8. Caplan LR (2002) Treatment of patients with stroke. Arch Neurol 59:703–707

    Article  PubMed  Google Scholar 

  9. Heuschmann PU, Berger K, Misselwitz B, Hermanek P, Leffmann C,Adelmann M, Buecker-Nott HJ, Rother J,Neundoerfer B,Kolominsky-Rabas PL (2003) Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality. The German Stroke Registers Study Group. Stroke 34:1106–1113

    Article  Google Scholar 

  10. Muir KW, Grosset DG (1999) Neuroprotection for acute stroke: making clinical trials work. Stroke 30:180–182

    PubMed  Google Scholar 

  11. Szoeke CE, Parsons MW, Butcher KS, Baird TA, Mitchell PJ, Fox SE, Davis SM (2003) Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital. Med J Aust 178:324–328

    PubMed  Google Scholar 

  12. Albers GW, Goldstein LB, Hall D, Lesko LM, for the Aptiganel Acute Stroke Investigators (2001) Aptiganel in acute ischemic stroke. A randomized controlled trial. JAMA 286:2673–2678

    Article  PubMed  Google Scholar 

  13. Jensen BS (2002) BMS-204352: a potassium channel opener developed for the treatment of stroke. CNS Drug Reviews 8:353–360

    PubMed  Google Scholar 

  14. Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, et al. (2000) Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 31:347–354

    PubMed  Google Scholar 

  15. Davalos A, Castillo J, Alvarez-Sabin J, Secades JJ, Mercadal J, Lopez S, et al. (2002) Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke 33:2850–2857

    Article  PubMed  Google Scholar 

  16. Clark WM, Williams BJ, Selzer KA, Zweifler RM, Sabounjian LA, Gammans RE (1999) A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 30:2592–2597

    PubMed  Google Scholar 

  17. Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE (2001) A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 57:1595–1602

    PubMed  Google Scholar 

  18. Wahlgren NG, Ranasinha KW, Rosolacci T, et al. (1999) Clomethiazole Acute Stroke Study (CLASS). Results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients. Stroke 30:21–28

    PubMed  Google Scholar 

  19. Lyden P, Shuaib A, Ng K, Levin K, et al. (2002) Clomethiazole Acute Stroke Study in Ischemic Stroke (CLASS-I). Final results. Stroke 33:122–129

    Article  PubMed  Google Scholar 

  20. Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, et al. (1998) Ebselen in acute ischemic stroke: a placebo-controlled, doubleblind clinical trial. Ebselen Study Group. Stroke 29:12–17

    PubMed  Google Scholar 

  21. Enlimomab Acute Stroke Trial Investigators (2001) Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology 57:1428–1434

    PubMed  Google Scholar 

  22. Lees KR, Asplund K, Carolei A, Davis SM, Diener H-C, Kaste M, Orgogozo J-M, Whitehead J, for the GAIN International Investigators (2000) Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. Lancet 355:1949–1950

    Article  PubMed  Google Scholar 

  23. Sacco RL, DeRosa JT,Haley EC Jr, Levin B, Ordronneau P, Phillips SJ, et al. (2001) Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA 285:1719–1728

    Article  PubMed  Google Scholar 

  24. Diener HC (1998) Multinational randomized trial of lubeluzole in acute ischaemic stroke: European and Australian Lubeluzole Ischaemic Stroke Study Group. Cerebrovasc Dis 8:172–181

    Article  PubMed  Google Scholar 

  25. Diener HC, Cortens M, Ford G, et al. (2000) Lubeluzole in acute ischemic stroke treatment a double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke 31:2543–2551

    PubMed  Google Scholar 

  26. Grotta J (1997) Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group. Stroke 28:2338–2346

    PubMed  Google Scholar 

  27. Clark W, Ertag W, Orecchio E, Raps E (1999) Cervene in acute ischemic stroke: Results of a double-blind, placebo-controlled, dose-comparison study. J Stroke Cerebrovasc Dis 8:224–230

    Google Scholar 

  28. Clark WM, Raps EC, Tong DC, Kelly RE, for the Cervene Stroke Study Investigators (2000) Cervene (nalmefene) in acute ischemic stroke. Final results of a phase III efficacy study. Stroke 31:1234–1239

    PubMed  Google Scholar 

  29. De Deyn PP, De Reuck J, Deberdt W, Vlietinck R, Orgogozo JM, for the Members of the Piracetam in Acute Stroke Study (PASS) Group (1997) Treatment of acute ischemic stroke with piracetam. Stroke 28:2347–2352

    PubMed  Google Scholar 

  30. Tirilazad mesylate in acute ischemic stroke: A systematic review (2000) Tirilazad International Steering Committee. Stroke 31:2257–2265

    PubMed  Google Scholar 

  31. Bogousslavsky J, Victor SJ, Salinas EO, Pallay A, Donnan GA, Fieschi C, et al. (2002) Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial. Cerebrovasc Dis 14:239–251

    Article  PubMed  Google Scholar 

  32. http://www.dendron.com

  33. Stroke Therapy Academic Industry Roundtable II (STAIR-II) (2001) Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 32:1598–1606

    PubMed  Google Scholar 

  34. Gladstone DJ, Black SE, Hakim AM (2002) Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33:2123–2136

    Article  PubMed  Google Scholar 

  35. Grotta J (2002) Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke 33:306–307

    PubMed  Google Scholar 

  36. Lees KR, Hankey GJ, Hacke W (2003) Design of future acute-stroke treatment trials. Lancet Neurol 2:54–61

    Article  PubMed  Google Scholar 

  37. Stroke Therapy Academic Industry Roundtable (STAIR) (1998) Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30:2752–2758

    Google Scholar 

  38. Ikonomidou C, Turski L (2002) Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol 1:383–386

    PubMed  Google Scholar 

  39. Muir KW (2002) Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design. Stroke 33:1545–1550

    Article  PubMed  Google Scholar 

  40. Uchino K, Billheimer D, Cramer SC (2001) Entry criteria and baseline characteristics predict outcome in acute stroke trials. Stroke 32:909–916

    PubMed  Google Scholar 

  41. Yam PS, Dunn LT, Graham DI, Dewar D, McCulloch JNMD (2000) A receptor blockade fails to alter axonal injury in focal cerebral ischemia. J Cereb Blood Flow Metab 20:772–779

    PubMed  Google Scholar 

  42. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C (1991) Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 337:1521–1526

    Article  PubMed  Google Scholar 

  43. Jorgensen HS, Reith J, Nakayama H, Kammersgaard LP, Raaschou HO, Olsen TS (1999) What determines good recovery in patients with the most severe strokes? The Copenhagen Stroke Study. Stroke 30:2008–2012

    PubMed  Google Scholar 

  44. Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, et al. (2000) Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA 283:2395–2403

    Article  PubMed  Google Scholar 

  45. Wahlgren NG, Bornhov S, Sharma A, Cederin B, Rosolacci T, Ashwood T, et al. (1999) The clomethiazole stroke study (CLASS): Efficacy results in 545 patients classified as total anterior circulation syndrome (TACS). J Stroke Cerebrovasc Dis 8:231–239

    Google Scholar 

  46. Muir KW, Lees KR, Ford I, Davis S; Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators (2004) Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet 363:439–445

    Article  PubMed  Google Scholar 

  47. DeGraba TJ, Hallenbeck JM, Pettigrew KD, Dutka AJ, Kelly BJ (1999) Progression in acute stroke.Value of the initial NIH Stroke Scale score in patient stratification in future trials. Stroke 30:1208–1212

    PubMed  Google Scholar 

  48. The NINDS t-PA Stroke Study Group (1997) Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA stroke trial. Stroke 28: 2119–2125

    PubMed  Google Scholar 

  49. Grotta JC, Chiu D, Lu M, Patel S, Levine SR, Tilley BC, Brott TG, et al. (1999) Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rrtPA therapy. Stroke 30:1528–1533

    PubMed  Google Scholar 

  50. Warach S (2004) Early reperfusion related to clinical response in DIAS: phase II, randomized, placebocontrolled dose finding trial of IV desmoteplase 3–9 hours from onset in patients with diffusion-perfusion mismatch. Presented at the 29th International Stroke Conference, San Diego, California

  51. Marler JR, Tilley BC, Lu M, Brott TG, Lyden PC, Grotta JC, Broderick JP, Levine SR, Frankel MP, Horowitz SH, Haley EC Jr, Lewandowski CA, Kwiatkowski TP (2000) Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 55:1649–1655

    PubMed  Google Scholar 

  52. Hacke for the ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators (2004) Better outcome with early stroke treatment: A pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (in press)

  53. Kidwell CS, Liebeskind DS, Starkman S, Saver JL (2001) Trends in acute ischemic stroke trials through the 20th century. Stroke 32:1349–1359

    PubMed  Google Scholar 

  54. Sereghy T, Overgaard K, Boysen G (1993) Neuroprotection by excitatory amino acid antagonist augments the benefit of thrombolysis in embolic stroke in rats. Stroke 24:1702–1708

    PubMed  Google Scholar 

  55. Grotta J (2001) Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole. Cerebrovasc Dis 12:258–263

    Article  PubMed  Google Scholar 

  56. Liebeskind DS, Kasner SE (2001) Neuroprotection for ischaemic stroke: an unattainable goal? CNS Drugs 15:165–174

    PubMed  Google Scholar 

  57. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo J-M, Ford GA (2003) Acute stroke therapy by inhibition of neutrophils (ASTIN): An adaptive dose-response study of UK-279.276 in acute ischemic stroke. Stroke 34:2543–2548

    Article  PubMed  Google Scholar 

  58. Dorman J, Sandercock PA (1996) Consideration of the design of clinical trials of neuroprotective therapy in acute stroke. Stroke 27:1507–1515

    PubMed  Google Scholar 

  59. Samsa GP, Matchar DB (2001) Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles. Stroke 32:669–674

    PubMed  Google Scholar 

  60. Duncan PW, Jorgensen HS, Wade DT (2000) Outcome measures in acute stroke trials. A systematic review and some recommendations to improve practice. Stroke 31:1429–1438

    PubMed  Google Scholar 

  61. Roberts L, Counsell C (1998) Assessment of clinical outcomes in acute stroke trials. Stroke 29:986–991

    PubMed  Google Scholar 

  62. Young FB, Lees KR, Weir CJ for the Glycine Antagonist in Neuroprotection (GAIN) (2003) International Trial Steering Committee and Investigators. Stroke 34:2676–2680

    Article  PubMed  Google Scholar 

  63. Duncan PW, Wallace D, Lai SM, Johnson D, Embretson S, Laster LJ (1999) The stroke impact scale version 2.0. Evaluation of reliability, validity, and sensitivity to change. Stroke 30: 2131–2140

    PubMed  Google Scholar 

  64. Wilson JT, Hareendran A, Grant M, Baird T, Schulz UG, Muir KW, Bone I (2002) Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. Stroke 33:2243–2249

    Article  PubMed  Google Scholar 

  65. Weir CJ,Kaste M, Lees KR, for the GAIN International Steering Committee and Investigators (2003) Targeting neuroprotective clinical trials on patients with potential to benefit increases statistical power and reduces the sample size required. Presented at the International Stroke Conference, San Antonio, Texas

  66. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P (1998) Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352:1245–1251

    Article  PubMed  Google Scholar 

  67. Wardlaw JM, Sandercock PA, Warlow CP, Lindley RI (2000) Trials of thrombolysis in acute ischemic stroke: does the choice of primary outcome measure really matter? Stroke 31:1133–1135

    PubMed  Google Scholar 

  68. Stroke Unit Trialists’ Collaboration (2002) Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev 1:CD000197

    Google Scholar 

  69. Bode-Greuel KM, Klisch J, Horvath E, Glaser T, Traber J (1990) The effect of BAY x 3702 on hippocampal damage after transient forebrain ischemia in the Mongolian gerbil. Stroke 21:164–166

    Google Scholar 

  70. Horvath E, Augstein K-H, Wittka R (1997) Neuroprotective effect of the novel 5-HT1A receptor agonist BAY x 3702 in a rat model of permanent focal cerebral ischemia and traumatic brain injury (abstract). Soc Neurosci 23:1923

    Google Scholar 

  71. Horvath E, Augstein K-H (1997) Neuroprotection by the novel 5-HT1A receptor agonist BAY x 3702 in the rat model of acute subdural hematoma (abstract). J Neurotrauma 14:800

    Google Scholar 

  72. Teal P, on behalf of the BRAINS Study Group (1998) BRAINS, a phase II study of the neuroprotectant, BAY x 3702 in patients with ischemic stroke (abstract). Cerebrovasc Dis 8(Suppl 4):20

    Article  PubMed  Google Scholar 

  73. Teal P, Lyden P,Hennerici M,Kaste M, Davis SM, Sprenger K (2003) Design and rationale for the modification of a Randomized Exposure Control Trial of repinotan in acute ischemic stroke. Presented at the International Stroke Conference, Phoenix, Arizona

  74. Lees KR, Barer D, Ford GA, Hacke W, Kostulas V, Sharma AK, et al. (2003) Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke 34:482–487

    Article  PubMed  Google Scholar 

  75. Davis SM, Donnan GA (2002) Neuroprotection: establishing proof of concept in human stroke. Stroke 33:309–310

    Article  PubMed  Google Scholar 

  76. Lees KR, Sharma AK, Barer D, Ford GA,Kostulas V, Cheng Y-F, et al. (2001) Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke 32:675–680

    PubMed  Google Scholar 

  77. Hacke W (2004) The DIAS Study: results of a phase II, MRI-based dose finding study of desmoteplase in acute stroke. Presented at the 29th International Stroke Conference, San Diego, California

    Google Scholar 

  78. Peterson L, Prince HC,Williams B, Tempel D,Grotta JC (2002) ARTIST+: AMPA Receptor Antagonist Treatment in Ischemic Stroke Trial, YM872 + Alteplase. Ongoing Clinical Trials Session, 27th International Stroke Conference

  79. Yurko-Mauro KA, Prince HC,Williams B, Tempel D,Warach S, for the ARTIST MRI Study Group (2002) ARTIST MRI: AMPA Receptor Antagonist Treatment in Ischemic Stroke Trial-MRI. Ongoing Clinical Trials Session, 27th International Stroke Conference

    Google Scholar 

  80. Lodder J, van Raak L, Kessels F (2001) Early GABA-ergic activation study in stroke. Ongoing Clinical Trials Session, 26th International Stroke Conference

  81. van Raak L, Hilton A, Kessels F, Lodder J (2002) Implementing the EGASIS trial, an international multicenter acute intervention trial in stroke. Control Clin Trials 23:74–79

    Article  PubMed  Google Scholar 

  82. IMAGES Study Investigators (2004) Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet 363:414–415

    Article  PubMed  Google Scholar 

  83. Saver JL, Kidwell CS, Hamilton S, Stratton S, Eckstein M, Cohen S, et al. (2002) The Field Administration of Stroke Therapy – Magnesium (FAST-MAG) Phase 3 Trial. Ongoing Clinical Trials Session, 27th International Stroke Conference

  84. Bath PMW, Willmot MR, Weaver CW, Leonardi-Bee J, for the ENOS Investigators (2002) Efficacy of Nitric Oxide in Stroke (ENOS): A prospective, large, randomised controlled trial in acute stroke. British Association of Stroke Physicians Conference

Download references

Author information

Affiliations

  1. University of British Columbia, Vancouver, British Columbia, Canada

    Ph. A. Teal MD

  2. University of Glasgow, Division of Clinical Neurosciences, Institute of Neurological Sciences Southern General Hospital, Glasgow G51 4TF, Scotland

    K. W. Muir MD, FRCP

Authors
  1. K. W. Muir MD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ph. A. Teal MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Muir, K.W., Teal, P.A. Why have neuroprotectants failed?. J Neurol 252, 1011–1020 (2005). https://doi.org/10.1007/s00415-005-0933-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-005-0933-6